OR WAIT null SECS
© 2021 MJH Life Sciences and Contemporary OB/GYN. All rights reserved.
© 2021 MJH Life Sciences™ and Contemporary OB/GYN. All rights reserved.
December 01, 2021
Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
November 24, 2021
Attention needs to be paid to the psychosocial needs of patients, especially those with poor health-related quality of life, who have little support, or are single mothers.